ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse
- Conditions
- Brain and Central Nervous System Tumors
- Registration Number
- NCT00016991
- Lead Sponsor
- Duke University
- Brief Summary
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells and slow the growth of glioblastoma multiforme.
PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have glioblastoma multiforme in first relapse.
- Detailed Description
OBJECTIVES:
* Determine the activity of ZD 1839 in patients with glioblastoma multiforme in first relapse.
* Determine the pharmacokinetics and toxicity of this drug in these patients.
* Assess the relationship between epidermal growth factor receptor status in these patients and activity of this drug.
OUTLINE: Patients receive oral ZD 1839 once daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Patients are followed for at least 6 months.
PROJECTED ACCRUAL: A total of 53 patients will be accrued for this study within 12-18 months.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Duke Comprehensive Cancer Center
🇺🇸Durham, North Carolina, United States
Duke Comprehensive Cancer Center🇺🇸Durham, North Carolina, United States